SCHEMBL13154442

SCHEMBL13154442

O=S(=O)(NCC(c1ccccc1)c1ccccc1)Nc1ccc(S(=O)(=O)Nc2nccs2)cn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN8A Q9UQD0 12/20 0.54
SCN1A P35498 9/20 0.54
SCN5A Q14524 9/20 0.54
SCN1B Q07699 7/20 0.54
SCN3A Q9NY46 3/20 0.52
SCN4A P35499 1/20 0.52
SCN9A Q15858 1/20 0.52
SCN2A Q99250 1/20 0.52
SCN10A Q9Y5Y9 1/20 0.52
LMNA P02545 2/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
CYP2C9 P11712 1/20 0.47
EDNRA P25101 1/20 0.47
SLC6A4 P31645 1/20 0.47
ADRA1A P35348 1/20 0.47
PRMT6 Q96LA8 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PKM P14618 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1350297 0.89 SCN8A (0.56) SCN8ASCN1ASCN5ASCN1BSCN3A
SCHEMBL13154447 0.85 SCN8A (0.65) SCN8ASCN1ASCN5ASCN1BSCN3A
SCHEMBL13154433 0.77 SCN1A (0.62) SCN8ASCN1ASCN5ASCN1BSCN3A
SCHEMBL326633 0.73 ALDH1A1 (0.71) SCN8ASCN1ASCN5ASCN1BSCN3A
Hydrochloric Acid SCHEMBL27575105 0.72 ALDH1A1 (0.69) SCN8ASCN1ASCN5ASCN1BSCN3A
SCHEMBL3070565 0.71 ALDH1A1 (0.68) SCN8ASCN1ASCN5ASCN1BSCN3A
SCHEMBL710141 0.71 ALDH1A1 (0.56) LMNAALDH1A1KDM4ECYP2C9EDNRA
SCHEMBL20238762 0.70 SCN8A (1.00) SCN8ASCN1ASCN5ASCN1BSCN3A
SCHEMBL20238763 0.70 SCN8A (1.00) SCN8ASCN1ASCN5ASCN1BSCN3A
SCHEMBL13154443 0.70 SCN8A (0.49) SCN8ASCN1ASCN5ASCN1BSCN3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338608-B2 Inhibitors of ion channels ICAGEN INC. (US) 2012-12-25 US disclosed
US-8338608-B2 Inhibitors of ion channels ICAGEN INC. (US) 2012-12-25 US disclosed
US-20100234343-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2010-09-16 US disclosed
US-20100234343-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2010-09-16 US disclosed
US-7705158-B2 Inhibitors of ion channels ICAGEN, INC. (US) 2010-04-27 US disclosed
US-7705158-B2 Inhibitors of ion channels ICAGEN, INC. (US) 2010-04-27 US disclosed
US-20070135493-A1 INHIBITORS OF ION CHANNELS ICAGEN (US) 2007-06-14 US disclosed
US-20070135493-A1 INHIBITORS OF ION CHANNELS ICAGEN (US) 2007-06-14 US disclosed
WO-2007056099-A2 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234343-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN8A 75/4885SCN1A 6/4885SCN5A 15/4885
US-20070135493-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN8A 75/4885SCN1A 6/4885SCN5A 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.